Omega Therapeutics Inc
NASDAQ:OMGA
Omega Therapeutics Inc
NASDAQ:OMGA
Price:
2.27 USD
-3.4%
Market Closed
Updated:
Apr 28, 2024
Section:
Relative Value
The Relative Value of one
OMGA
stock under the Base Case scenario is
0.44
USD.
Compared to the current market price of 2.27 USD,
Omega Therapeutics Inc
is
Overvalued by 81%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
OMGA
Relative Value
Base Case
0.44
USD
Overvaluation 81%
Valuation Multiples
Multiples Across Competitors
OMGA Competitors Multiples
Omega Therapeutics Inc Competitors
Omega Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Omega Therapeutics Inc
NASDAQ:OMGA
|
125.2m USD | 40.5 | -1.3 | -0.7 | -0.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
281.9B USD | 5.2 | 58.5 | 12.7 | 19.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
144.5B USD | 5.1 | 21.5 | 16.1 | 24.1 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
102.4B USD | 10.4 | 28.3 | 22.6 | 23.7 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
96.6B USD | 7.4 | 24.4 | 16.1 | 17.7 | |
| AU |
|
CSL Ltd
ASX:CSL
|
132B AUD | 6.1 | 34.9 | 21.2 | 26.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81.5B USD | 3 | 14.4 | 7.9 | 10.2 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
41.2B USD | 6 | -8.7 | -9.2 | -7.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
30.3B USD | 3.1 | 26.1 | 14.2 | 17.6 | |
| KR |
|
Celltrion Inc
KRX:068270
|
36.6T KRW | 16.8 | 68.3 | 41.9 | 57.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
